A Look Ahead: Varex Imaging's Earnings Forecast
Benzinga Insights 8 months ago
Earnings
Varex Imaging (NASDAQ:VREX) will release its quarterly earnings report on Tuesday, 2026-02-10. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Varex Imaging to report an earnings per share (EPS) of $0.13.
The market awaits Varex Imaging's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
Earnings History Snapshot
Last quarter the company beat EPS by $0.19, which was followed by a 13.66% drop in the share price the next day.
Here's a look at Varex Imaging's past performance and the resulting price change:
| Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| EPS Estimate | 0.18 | 0.04 | 0.14 | 0.04 |
| EPS Actual | 0.37 | 0.18 | 0.26 | 0.07 |
| Price Change % | -14.00 | 21.00 | -20.00 | -19.00 |
Tracking Varex Imaging's Stock Performance
Shares of Varex Imaging were trading at $14.0 as of February 06. Over the last 52-week period, shares are up 4.44%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
Analyst Observations about Varex Imaging
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Varex Imaging.
The consensus rating for Varex Imaging is Buy, based on 2 analyst ratings. With an average one-year price target of $17.0, there's a potential 21.43% upside.
Understanding Analyst Ratings Among Peers
The analysis below examines the analyst ratings and average 1-year price targets of Beta Bionics, Tactile Systems Tech and NeuroPace, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
- Analysts currently favor an Buy trajectory for Beta Bionics, with an average 1-year price target of $29.5, suggesting a potential 110.71% upside.
- Analysts currently favor an Outperform trajectory for Tactile Systems Tech, with an average 1-year price target of $35.0, suggesting a potential 150.0% upside.
- Analysts currently favor an Buy trajectory for NeuroPace, with an average 1-year price target of $20.33, suggesting a potential 45.21% upside.
Comprehensive Peer Analysis Summary
In the peer analysis summary, key metrics for Beta Bionics, Tactile Systems Tech and NeuroPace are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|---|---|---|---|---|
| Varex Imaging | Buy | 11.28% | $77.80M | 2.63% |
| Beta Bionics | Buy | 63.14% | $15.12M | -4.76% |
| Tactile Systems Tech | Outperform | 17.32% | $65.00M | 4.11% |
| NeuroPace | Buy | 29.89% | $21.17M | -18.42% |
Key Takeaway:
Varex Imaging ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.
All You Need to Know About Varex Imaging
Varex Imaging Corp Designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, detectors, ionization chambers, high-voltage connectors, software, collimators, generators, exposure control devices, and heat exchangers.. The company operates through two segments: Medical, the key revenue driver, providing X-ray imaging components and accessories for healthcare applications, and Industrial, which provides Linatron X-ray accelerators, X-ray tubes, flat panel detectors, high-voltage connectors, and coolers for non-medical use. Geographically, it generates the majority of its revenue from Europe, the Middle East, and Africa (EMEA), with the rest coming from the Americas and Asia Pacific.
Varex Imaging's Economic Impact: An Analysis
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Varex Imaging displayed positive results in 3 months. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 11.28%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Varex Imaging's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.33% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Varex Imaging's ROE stands out, surpassing industry averages. With an impressive ROE of 2.63%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Varex Imaging's ROA excels beyond industry benchmarks, reaching 1.12%. This signifies efficient management of assets and strong financial health.
Debt Management: Varex Imaging's debt-to-equity ratio stands notably higher than the industry average, reaching 0.84. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
To track all earnings releases for Varex Imaging visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.